tldrdailynews.com logo

Vertex’s IgA nephropathy drug halves a key kidney biomarker in Phase 3

1 min read
Source: statnews.com
Vertex’s IgA nephropathy drug halves a key kidney biomarker in Phase 3
Photo: statnews.com
TL;DR

Vertex reported Phase 3 data showing its IgA nephropathy drug reduced a key kidney-disease biomarker by about 50%, in a three-way race with Otsuka and Vera Therapeutics and signaling potential multi-billion-dollar annual sales.

Topics:businesshealthcare#biotech#healthcare#iga-nephropathy#kidney-disease#phase-3-trial#vertex-pharma
Share this article
  1. Vertex says its drug successfully reduced marker of kidney disease in late-stage trial  statnews.com
  2. Vertex races to FDA after phase 3 kidney disease data impress analysts  Fierce Biotech
  3. Vertex's kidney disease drug meets main goal in late-stage trial  AOL.com
  4. Vertex's $4.9B kidney disease bet hits key milestone  The Business Journals
  5. Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy  Business Wire

Want the full story? Read the original reporting

Read on statnews.com